Findings

What do systematic reviews say?

32 questions · 32 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 3.1%GRADE not reported 2 · 6.3%Very low 0 · 0%Low 10 · 31.3%Moderate 15 · 46.9%High 4 · 12.5%

DOAC vs variable dose warfarin

Major bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in major bleeding compared with warfarin (low certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.79 [0.59, 1.04]
5 studies · 12521 participants
Low

DOAC vs variable dose warfarin

Myocardial infarction · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in myocardial infarction compared with warfarin; GRADE not reported.

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.92 [0.45, 1.9]
1 study · 2740 participants
GRADE not reported

DOAC vs variable dose warfarin

Minor bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in minor bleeding compared with warfarin (low certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.97 [0.58, 1.61]
2 studies · 3012 participants
Low

DOAC vs variable dose warfarin

Gastrointestinal bleeding · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in gastrointestinal bleeding compared with warfarin (moderate certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 1.4 [0.97, 2.01]
2 studies · 5678 participants
Moderate

DOAC vs variable dose warfarin

Intracranial haemorrhage · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) probably leads to lower intracranial haemorrhage compared with warfarin (moderate certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.43 [0.27, 0.69]
5 studies · 12521 participants
Moderate

DOAC vs variable dose warfarin

All‐cause mortality · atrial fibrillation patients with CKD

Direct oral anticoagulants (DOAC) showed no clear difference in all‐cause mortality compared with warfarin (moderate certainty).

1 finding from 1 review

Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation… 2017 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.05]
4 studies · 9595 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.94 [0.64, 1.38]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.48 [0.24, 0.98]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.61 [0.31, 1.21]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 1.65 [0.72, 3.8]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 3.58 [0.55, 23.44]
3 studies · 1440 participants
Low

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found